Table 5.
Clinical characteristics and results of studies assessing the adverse events and outcomes of alfuzosin in combination with other drugs for the treatment of benign prostatic hyperplasia.
| Study (author) | Study type | Duration (weeks) | Treatment (drug and daily dose) | Patients (n) | Change in symptoms (IPSS) (% or mean ± SD) | Change in Qmax (mL/s) | PVR change (mL) | Adverse events (%) |
|---|---|---|---|---|---|---|---|---|
| Alfuzosin and 5-α reductase inhibitors | ||||||||
| Debruyne et al.a | RCT | 26 | Alfuzosin 5 mg BID Finasteride 5 mg Alfuzosin 5 mg BID plus Finasteride 5 mg |
358 344 349 |
−41.2% −33.5% −39.1% (p = 0.009) |
1.8 1.8 2.3 (NS) |
/// | 1.7% 2.9% 2.3% (NS) |
| Alfuzosin and muscarinic receptor antagonists | ||||||||
| Bae et al.b | RCT | 10 | Alfuzosin 10 mg Alfuzosin 10 mg plus Propiverine 10 mg |
77 132 |
−7.8 −8.3 (p = 0.031) |
7.1 5.8 (NS) |
11.2 15.6 (NS) |
3.9% 6.8% (NS) |
| Cho et al.c | RCT | 8 | Alfuzosin 10 mg Alfuzosin 10 mg plus Propiverine 10 mg Alfuzosin 10 mg plus Propiverine 20 mg |
43 48 44 |
−4.67 (±5.83) −5.92 (±7.77) −6.56 (±9.60) (NS) |
0.91 (±6.57) 1.95 (±6.29) 3.03 (±10.18) (NS) |
5.44 (±20.15) 1.56 (±27.3) 26.3 (±72.5) (NS) |
2% 8% 18% (NS) |
| Alfuzosin and PDE5 inhibitors | ||||||||
| Kaplan et al.d | RCT | 12 | Alfuzosin 10 mg Sildenafil 25 mg Alfuzosin 10 mg plus Sildenafil 25 mg |
20 21 21 |
15.6% 16.9% 24.1% (p = 0.03) |
11.7% 6.2% 21.1% |
42.6% 26.1% 39.6% |
/// |
| Liguori et al.e | RCT | 12 | Alfuzosin 10 mg Tadalafil 20 mg Alfuzosin 10 mg plus Tadalafil 20 mg |
22 21 23 |
27.2% 8.4% 41.6% |
21.7% 9.5% 29.6% |
/// | /// |
| Ozturk et al.f | RCT | 12 | Alfuzosin 10 mg Alfuzosin 10 mg plus Sildenafil 50 mg |
50 50 |
26.8% 28.2% (NS) |
29.6% 33% (NS) |
23% 26.2% (NS) |
/// |
| Kumar et al.g | RCT | 12 | Alfuzosin 10 mg Tadalafil 10 mg Alfuzosin 10 mg plus Tadalafil 10 mg |
25 25 25 |
−9.5 (±3.5) −6.3 (±1.5) −12.3 (±2.8) (p < 0.004) |
−3.6 (±1.9) −1.9 (±2) −4.1 (±1.4) |
−22.8 (±24.5) −14.6 (±16.4) −56.1 (±46.2) (p > 0.003) |
/// |
Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN study group. Eur Urol 1998; 34: 169–175.
Bae JH, Kim SO, Yoo ES, et al. Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial. Korean J Urol 2011; 52: 274–278.
Cho HJ, Shin SC, Seo DY, et al. Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study. Int J Clin Pract 2014; 68: 471–477.
Kaplan SA, Gonzalez RR and Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717–1723.
Liguori G, Trombetta C, De Giorgi G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009; 6: 544–552.
Ozturk MI, Kalkan S, Koca O, et al. Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. Andrologia 2012; 44: 791–795.
Kumar S, Kondareddy C, Ganesamoni R, et al. Randomized controlled trial to assess the efficacy of the combination therapy of alfuzosin and tadalafil in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Low Urin Tract Symptoms 2014; 6: 35–40.
IPSS: International Prostate Symptom Score; NS: non significant; PVR: post-voided residual; RCT: randomized clinical trial.